Cargando…
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete response (pCR) and 5-year outcomes in patients with early-stage b...
Autores principales: | Whitworth, Pat W., Beitsch, Peter D., Murray, Mary K., Richards, Paul D., Mislowsky, Angela, Dul, Carrie L., Pellicane, James V., Baron, Paul L., Rahman, Rakhshanda Layeequr, Lee, Laura A., Dupree, Beth B., Kelemen, Pond R., Ashikari, Andrew Y., Budway, Raye J., Lopez-Penalver, Cristina, Dooley, William, Wang, Shiyu, Dauer, Patricia, Menicucci, Andrea R., Yoder, Erin B., Finn, Christine, Blumencranz, Lisa E., Audeh, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489196/ https://www.ncbi.nlm.nih.gov/pubmed/36108259 http://dx.doi.org/10.1200/PO.22.00197 |
Ejemplares similares
-
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
por: Whitworth, Pat, et al.
Publicado: (2022) -
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature
por: Whitworth, Pat W., et al.
Publicado: (2022) -
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Blumencranz, Peter, et al.
Publicado: (2023) -
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
por: Whitworth, Pat, et al.
Publicado: (2016) -
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
por: Groenendijk, Floris H., et al.
Publicado: (2019)